Nothing Special   »   [go: up one dir, main page]

MXPA01008612A - Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses. - Google Patents

Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses.

Info

Publication number
MXPA01008612A
MXPA01008612A MXPA01008612A MXPA01008612A MXPA01008612A MX PA01008612 A MXPA01008612 A MX PA01008612A MX PA01008612 A MXPA01008612 A MX PA01008612A MX PA01008612 A MXPA01008612 A MX PA01008612A MX PA01008612 A MXPA01008612 A MX PA01008612A
Authority
MX
Mexico
Prior art keywords
epsilon
ige
epitopes
domains
antagonists
Prior art date
Application number
MXPA01008612A
Other languages
Spanish (es)
Inventor
Martin Friede
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904408.3A external-priority patent/GB9904408D0/en
Priority claimed from GBGB9917144.9A external-priority patent/GB9917144D0/en
Priority claimed from GBGB9918598.5A external-priority patent/GB9918598D0/en
Priority claimed from GBGB9918604.1A external-priority patent/GB9918604D0/en
Priority claimed from GBGB9918599.3A external-priority patent/GB9918599D0/en
Priority claimed from GBGB9918601.7A external-priority patent/GB9918601D0/en
Priority claimed from GBGB9918606.6A external-priority patent/GB9918606D0/en
Priority claimed from GBGB9925618.2A external-priority patent/GB9925618D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of MXPA01008612A publication Critical patent/MXPA01008612A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the provision of novel medicaments for the treatment, prevention or amelioration of allergic disease. In particular, the novel medicaments are epitopes or mimotopes derived from the Cepsilon3 or Cepsilon4 domains of IgE. These novel regions may be the target for both passive and active immunoprophylaxis or immunotherapy. The invention further relates to methods for production of the medicaments, pharmaceutical compositions containing them and their use in medicine. Also forming an aspect of the present invention are ligands, especially monoclonal antibodies, which are capable of binding the IgE regions of the present invention, and their use in medicine as passive immunotherapy or immunoprophylaxis.
MXPA01008612A 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses. MXPA01008612A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB9904408.3A GB9904408D0 (en) 1999-02-25 1999-02-25 Vaccine
GBGB9917144.9A GB9917144D0 (en) 1999-07-21 1999-07-21 Vaccine
GBGB9918598.5A GB9918598D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918604.1A GB9918604D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918599.3A GB9918599D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918601.7A GB9918601D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918606.6A GB9918606D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9925618.2A GB9925618D0 (en) 1999-10-29 1999-10-29 Vaccine
PCT/EP2000/001456 WO2000050461A1 (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses

Publications (1)

Publication Number Publication Date
MXPA01008612A true MXPA01008612A (en) 2003-06-24

Family

ID=27571340

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01008612A MXPA01008612A (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses.

Country Status (18)

Country Link
EP (1) EP1155038A1 (en)
JP (1) JP2002537403A (en)
KR (1) KR20020007314A (en)
CN (1) CN1520423A (en)
AR (1) AR029619A1 (en)
AU (1) AU3281100A (en)
CA (1) CA2363641A1 (en)
CO (1) CO5231139A1 (en)
CZ (1) CZ20013081A3 (en)
HK (1) HK1043134A1 (en)
HU (1) HUP0105490A3 (en)
IL (1) IL145025A0 (en)
MX (1) MXPA01008612A (en)
NO (1) NO20014131L (en)
NZ (1) NZ513680A (en)
PL (1) PL350992A1 (en)
TR (1) TR200102493T2 (en)
WO (1) WO2000050461A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2206701A (en) * 1999-12-21 2001-07-03 Acambis Research Limited A reversible linkage technology for controlled conjugation
EP1278542A2 (en) 2000-05-05 2003-01-29 Cytos Biotechnology AG Molecular antigen arrays and vaccines
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
JP2003047482A (en) * 2001-05-22 2003-02-18 Pfizer Prod Inc IgE VACCINE FREE FROM ANAPHYLAXIS-INDUCING PROPERTY
ES2335979T3 (en) 2001-09-14 2010-04-07 Cytos Biotechnology Ag IMMUNOSTIMULATOR CPG PACKAGING IN VIRUS SIMILAR PARTICLES: PREPARATION METHOD AND ITS USE.
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
CN1668637B (en) 2002-07-17 2010-05-26 希托斯生物技术股份公司 Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
WO2004009116A2 (en) 2002-07-18 2004-01-29 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
ATE506964T1 (en) 2002-07-19 2011-05-15 Cytos Biotechnology Ag VACCINE COMPOSITIONS CONTAINING AMYLOID BETA 1-6 ANTIGEN ARRAYS
AU2004224761A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
KR20070008578A (en) * 2004-02-02 2007-01-17 타녹스 인코퍼레이티드 Identification of novel ige epitopes
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
AU2006297304B2 (en) 2005-09-29 2012-05-17 Medimmune, Llc Method of identifying membrane LG specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
CA2636139A1 (en) 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
KR101552227B1 (en) 2006-06-12 2015-09-10 사이토스 바이오테크놀로지 아게 - processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
NZ592977A (en) 2008-12-09 2013-01-25 Pfizer Vaccines Llc IgE CH3 PEPTIDE VACCINE
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
EP2862873B1 (en) * 2012-06-18 2020-04-29 Nippon Zenyaku Kogyo Co., Ltd. IgE PEPTIDE VACCINE
AU2019247321A1 (en) * 2018-04-06 2020-10-22 Slsbio Co., Ltd. Novel epitope of immunoglobulin E, antibody binding thereto, and kit for analyzing immunoglobulin E in sample containing same
US20240245190A1 (en) 2023-01-19 2024-07-25 Sharkninja Operating Llc Identification of hair care appliance attachments

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02229200A (en) * 1989-02-28 1990-09-11 Dainippon Pharmaceut Co Ltd Peptide having anti-allergic activity
ATE233813T1 (en) * 1991-08-14 2003-03-15 Genentech Inc MODIFIED IMMUNOLOBULINS FOR SPECIFIC FC-EPSILON RECEPTORS
US6610297B1 (en) * 1996-03-01 2003-08-26 Novartis Ag Peptide immunogens for vaccination against and treatment of allergy
WO1998024808A2 (en) * 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate

Also Published As

Publication number Publication date
EP1155038A1 (en) 2001-11-21
WO2000050461A1 (en) 2000-08-31
NZ513680A (en) 2001-09-28
AU3281100A (en) 2000-09-14
HUP0105490A3 (en) 2002-05-28
HK1043134A1 (en) 2002-09-06
CZ20013081A3 (en) 2002-02-13
NO20014131D0 (en) 2001-08-24
AR029619A1 (en) 2003-07-10
JP2002537403A (en) 2002-11-05
IL145025A0 (en) 2002-06-30
CA2363641A1 (en) 2000-08-31
TR200102493T2 (en) 2002-02-21
CO5231139A1 (en) 2002-12-27
NO20014131L (en) 2001-10-02
PL350992A1 (en) 2003-02-24
KR20020007314A (en) 2002-01-26
HUP0105490A2 (en) 2002-04-29
CN1520423A (en) 2004-08-11

Similar Documents

Publication Publication Date Title
MXPA01008612A (en) Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses.
DE60028970D1 (en) AT HER2 BINDING PEPTIDE COMPOUNDS
AU3651802A (en) Recombinant anti-cd30 antibodies and uses thereof
WO2006002177A3 (en) Interferon alpha receptor 1 antibodies and their uses
UA90457C2 (en) Human monoclonal antibody that specifically binds to human m-csf
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
SG145712A1 (en) Crystalline tumor necrosis factor receptor 2 polypeptides
WO2002089738A3 (en) Proteomimetic compounds and methods
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
WO2003092624A3 (en) Use of heat shock proteins to enhance efficacy of antibody therapeutics
MXPA01008613A (en) Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses.
ATE235551T1 (en) LIGAND (TIE LIGAND-4) FROM TIE-2 RECEPTOR AND ITS USES
HK1063601A1 (en) Compositions and methods for treating hyperimmune response in the eye
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
WO2002026781A3 (en) Ige receptor antagonists
WO2004046096A3 (en) Novel ligands that are antagonists of raf receptors, process for preparing them and use thereof in human medicine and in cosmetics
WO2003092714A3 (en) Peptide variants of ige constrained by beta-lactam bond
WO2002034288A8 (en) Vaccine for treating allergy
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004078130A3 (en) Posh interacting proteins and related methods
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004004649A3 (en) Compositions and methods for the treatment of immune related diseases
UA83988C2 (en) Monoclonal andidual integrine antibody, specifically binding human integrines alpha v beta 3 and alpha v beta 5, pharmaceutical composition, containing it, and its use in therapy